Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Recently, growing body of evidence support the finding that anemia frequently occurs in
patients with chronic heart failure (CHF). Chronic kidney disease (CKD), as well, is highly
prevalent among heart failure patients, and both anemia and CKD are independently associated
with increased mortality. A vicious circle is established with CHF causing both chronic renal
insufficiency and anemia, and CKD further aggravating anemia which, in turn, worsens CHF and
so on. Treatment of the anemia breaks this circle and improves the quality of life, cardiac
and renal functions in patients with severe CHF.
Intravenous iron alone was proved to allow the maintenance of target hematocrit in one-third
of chronic renal failure predialysis patients.
Based on these considerations, intravenous iron for anemia in patients with CHF and moderate
CKD would represent a reasonable therapeutic approach.
The aim of the trial is to assess the efficiency of intravenous iron therapy in the
management of mild to moderate anemia associated with CHF NYHA III class and concomitant
moderate CKD.